profit from every $100 of sales.
$0$100
Purple Biotech
$1.63+4.49% today
-78.0% in 1 year
1-year low $0.921-year high $8.74
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Purple Biotech sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$26.4 million of profit last year.
SalesProfit
Purple Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Purple Biotech | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Purple Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -23 | -22 | -11 | -7 | |
| -21 | -20 | -7 | -26 | |
| -22 | -20 | -7 | -26 | |
| -240.00 | -178.00 | -44.16 | -54.00 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 55 | 44 | 37 | 18 |
| Cash | 15 | 14 | 7 | 9 |
| Total debt | 1 | 0 | 0 | 0 |
| Total liabilities | 8 | 10 | 4 | 8 |
| 47 | 34 | 33 | 10 | |
| 0 | 0 | 0 | 0 | |
| -36.1% | -45.5% | -17.3% | -209.9% | |
| -46.2% | -58.1% | -22.0% | -271.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -17 | -20 | -14 | -6 | |
| 0 | 0 | – | 0 | |
| -17 | -20 | -14 | -6 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 2 | 2 | 1 | 0 |
Valuation
- –
- –
- –
- 0.3×
- –
- –
- 1.2×
- -208.9%
- -1,011.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -295.3%
- -73.0%
- -98.5%
- -150.2%
- -302.6%
- –
Growth
- –
- –
- +61.4%
- –
- −59.7%
Financial health
- 1.5×
- 0.03
- 1.4%
- -115.0×
- 1.27
- 1.27
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.09 | -0.38 | +76.3% |
| Mar 13, 2026 | -19.85 | -3.40 | −483.8% |
| Nov 14, 2025 | -0.29 | -0.26 | −11.5% |
| Aug 6, 2025 | -0.40 | -0.21 | −90.5% |
| May 21, 2025 | -0.17 | – | – |
| Mar 10, 2025 | -0.26 | -0.22 | −18.2% |
| Nov 15, 2024 | -1.37 | -1.20 | −14.2% |
| Aug 16, 2024 | -1.60 | -0.16 | −900.0% |
News
Purple expects $15M-$20M 2026 adjusted EBITDA amid wholesale reset and plans for 60 showroomsSeeking Alpha · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
64Pass
Philip Fisher
28No pass
Peter Lynch
60Pass
Joel Greenblatt
100Pass
Charlie Munger
15No pass
Terry Smith
14No pass
Questions about Purple Biotech
Is Purple Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Purple Biotech AI analysis
What does Purple Biotech do?
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. It is in Biotechnology.
Does Purple Biotech pay a dividend?
No. Purple Biotech does not pay a dividend at the moment.
Is Purple Biotech stock halal?
No. Purple Biotech does not pass our halal screen: its cash and confirmed interest-bearing investments are 329% of its market value, at or above the 33% limit. How we check
How has Purple Biotech stock done over the past year?
Down 78.0% over the past twelve months, to $1.63. It traded between $0.92 and $8.74 and is 81.4% below its high.
Who are Purple Biotech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Purple Biotech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.